The stock of Axovant Sciences Ltd (NYSE:AXON) is a huge mover today! About 114,773 shares traded hands. Axovant Sciences Ltd (NYSE:AXON) has declined 2.68% since April 5, 2016 and is downtrending. It has underperformed by 4.63% the S&P500.
The move comes after 8 months positive chart setup for the $1.19 billion company. It was reported on Nov, 7 by Barchart.com. We have $18.80 PT which if reached, will make NYSE:AXON worth $666.40 million more.
Axovant Sciences Ltd (NYSE:AXON) Ratings Coverage
Out of 4 analysts covering Axovant Sciences (NYSE:AXON), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Axovant Sciences has been the topic of 4 analyst reports since September 25, 2015 according to StockzIntelligence Inc. Piper Jaffray initiated the stock with “Overweight” rating in Thursday, October 22 report. The firm has “Outperform” rating given on Tuesday, June 7 by Leerink Swann. The rating was initiated by H.C. Wainwright with “Buy” on Friday, January 8. The firm earned “Sell” rating on Friday, September 25 by Chardan Capital Markets.
According to Zacks Investment Research, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda.”
More notable recent Axovant Sciences Ltd (NYSE:AXON) news were published by: Prnewswire.com which released: “Axovant Sciences Ltd. Announces Pricing of Initial Public Offering” on June 11, 2015, also Prnewswire.com with their article: “Axovant Sciences Ltd. Announces Completion of Initial Public Offering and Full …” published on June 16, 2015, Fool.com published: “Why Axovant Sciences Skyrocketed 56% in November” on December 03, 2015. More interesting news about Axovant Sciences Ltd (NYSE:AXON) were released by: Investorplace.com and their article: “Why Axovant Sciences Ltd (AXON), Jabil Circuit, Inc. (JBL) and Virgin America …” published on September 22, 2016 as well as Fool.com‘s news article titled: “Why Axovant Sciences Shares Are Crashing” with publication date: February 03, 2016.
AXON Company Profile
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., incorporated on October 31, 2014, is a clinical-stage biopharmaceutical firm focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Firm focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.